stockrowXenon Pharmaceuticals Inc.
XENE Healthcare Biotechnology
Xenon Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 20.5% from fiscal 2022.
- Revenue
- +100.7%
- EPS
- −3.74%
- Free cash flow
- −48.6%
Quarter to June 2026, against a year earlier
Follow XENE
Alert me
Xenon Pharmaceuticals Inc. (XENE) EV/Sales
As of 5 November 2026, Xenon Pharmaceuticals Inc. (XENE) trades at a EV/Sales of 169×. Over the past ten years it has ranged from −9.3× (August 2017) to 593× (July 2019); the current reading is higher than 72% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 179× | 39.42% |
| FY2022 | 128× | 182.45% |
| FY2021 | 45.4× | 283.77% |
| FY2020 | 11.8× | (60.72%) |
| FY2019 | 30.1× | (37.24%) |
| FY2017 | 48.0× | 50.64% |
| FY2016 | 31.9× | 783.90% |
| FY2015 | 3.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2025 | 125× | (6.00%) |
| Sep 2022 | 133× | 196.98% |
| Jun 2022 | 44.8× | (12.22%) |
| Mar 2022 | 51.0× | 12.28% |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VKTX Viking Therapeutics, Inc. compare | n/m |
| PBLS Parabilis Medicines, Inc. compare | n/m |
| IRON Disc Medicine, Inc. compare | n/m |
| ACAD ACADIA Pharmaceuticals Inc. compare | 2.2× |
| IOVA Iovance Biotherapeutics, Inc. compare | 8.5× |
| TNGX Tango Therapeutics, Inc. compare | 34.7× |
| ABCL AbCellera Biologics Inc. compare | 43.5× |
| XENE Xenon Pharmaceuticals Inc. | 169× |
| RLAY Relay Therapeutics, Inc. compare | 231× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on XENE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement